CytomX Therapeutics, Inc.
CTMXCytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer treatments using its proprietary Probody technology. This platform employs antibody masks that remain inactive until they reach the tumor site, aiming to improve safety and efficacy by reducing off-target effects. Founded in 2011 and based in South San Francisco, CytomX collaborates with various pharmaceutical partners to advance immuno-oncology and targeted cancer therapies.
Company News
CytomX Therapeutics expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally-activated bispecific cancer therapies combining CytomX's PROBODY platform with Regeneron's Veloci-Bi platform. CytomX will receive $37 million for two additional programs, with potential total milestones reaching approximately $4 billion across ...
CytomX Therapeutics announced that management will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company will host fireside chats and one-on-one investor meetings at both events. CytomX is a clinical-stage biopharmaceutical company de...
The article compares small-cap and megacap healthcare stocks, using CytomX Therapeutics and Johnson & Johnson as examples. Small-cap stocks like CTMX offer higher growth potential but carry significant risk with no approved drugs and substantial losses. Megacap stocks like JNJ provide stability, consistent revenue growth, and dividend payments, t...
CytomX Therapeutics priced a $250 million underwritten public offering of 45.99 million shares at $5.30 per share and pre-funded warrants. The company plans to use net proceeds for development of Varseta-M and other pipeline programs. The offering is expected to close on March 19, 2026.
CytomX Therapeutics announced that management will participate in two upcoming conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 in New York and World ADC London on February 25 in London. The clinical-stage biopharmaceutical company, focused on conditionally activated biologics for oncology, continues to ...
